Prudential Financial Inc. Decreases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Prudential Financial Inc. decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 17.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 125,985 shares of the medical equipment provider’s stock after selling 26,661 shares during the period. Prudential Financial Inc. owned approximately 0.06% of Hologic worth $9,082,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. General Partner Inc. bought a new position in shares of Hologic during the fourth quarter valued at about $26,000. Venturi Wealth Management LLC boosted its holdings in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC grew its position in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares during the period. Finally, Smithfield Trust Co lifted its position in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research note on Monday, February 3rd. Evercore ISI decreased their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Wolfe Research began coverage on shares of Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Royal Bank of Canada reduced their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Finally, Raymond James reiterated an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $61.32 on Friday. The company has a 50 day simple moving average of $65.24 and a two-hundred day simple moving average of $73.29. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The company has a market capitalization of $13.76 billion, a price-to-earnings ratio of 19.34, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.